about
Are maintenance and continuous therapies indicated for every patient with multiple myeloma?Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.Next-generation sequencing of a family with a high penetrance of monoclonal gammopathies for the identification of candidate risk alleles.Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis.The OECI model: the experience of INT Milan with a focus on the integration of psycho-oncology support.Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis.New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogenic hematopoietic stem cell transplantation for hematological malignancies: two case reports.Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma.A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma.Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma.Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation.Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.Successful second autologous engraftment after long duration storage of hematopoietic stem cells.Effective treatment of pomalidomide in central nervous system myelomatosis.Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma.The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation.Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry.Late onset of hepatitis B virus reactivation following hematopoietic stem cell transplantation: successful treatment with combined entecavir plus tenofovir therapy.Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates.Does the addition of thalidomide to MP or low-intensity SCT improve survival in elderly multiple myeloma patients?Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation.Allogeneic stem cell transplantation and subsequent treatments as a comprehensive strategy for long-term survival of multiple myeloma patients.Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation.Peripheral blood stem cell collection in multiple myeloma: a retrospective analysis of 6 years leukapheresis activity in 109 patients treated at the Istituto Nazionale dei Tumori of Milan.Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed.Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor.Response-adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression-free survival in transplanted patients with multiple myeloma.Panobinostat in combination with bortezomib and dexamethasone as induction therapy in patients with multiple myeloma, candidates for autologous transplant.Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma.Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myelomaBortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 studyCarfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 studyReal-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state
P50
Q30249790-1138B59A-D779-4591-AADE-0C4C1301BCDDQ30595175-ADD0B9E3-C0A6-4ADA-8599-1EE59032ACB8Q33387698-B1F5E73D-F159-4C08-8CED-5798C76A5F00Q33409866-02E5FDB2-8355-466B-B596-255175FFB74CQ33412804-400C5454-795C-46D2-BAD6-D03005A729C1Q38764731-99DD0C46-B630-433E-8E91-8598B4BD3483Q38788692-CDD4B3D7-E919-40DF-AE66-7A55643865F9Q38812666-4B988880-15F2-400F-953C-262FED73FE23Q39070193-4F237188-36AA-46AF-9231-B78E40140B30Q39307476-BC7005BB-EBCB-46DB-9571-39FD20D7EFF1Q40154490-78914F9F-3833-416C-9842-3BBF12A26965Q40412896-7F1A6635-4CC3-45D5-807D-6B5D227EAB03Q40783660-514EF31A-75D5-49DC-9B7F-6092927B811BQ40845878-BAC09001-2564-448E-BA76-7D870F57E101Q42234475-38C12549-036B-4ACC-B97B-FC4CCDF0A60CQ42861085-EEE89D97-46A7-4709-9822-270B59CCC03FQ43553524-3CC346DF-F867-4825-9720-39F1440C5E0FQ43619471-02FED869-7FA7-4853-951D-305E23328FC2Q43640246-E332B86A-73A6-4896-8575-2B4814811CB3Q43670431-136EC296-1D21-49A7-A66D-A55976CB11BFQ43707069-D368C255-CC92-404F-AD06-2D93B2294570Q44292034-34ADC824-B24F-4DD9-83D3-DDEA06943629Q44359185-9544D6AC-BE84-4B12-871A-E66791B4D727Q45192496-5024C1C0-3A31-4E82-B836-DF1A3443A519Q45354799-409D2862-B068-40E0-9BDE-4C28CFE2C54FQ46694344-D740AA1D-D8C3-4C53-BB76-C5FACF671DE8Q47593295-8ADD30E2-13B6-49D1-99FB-F3999B3BD601Q48094910-125C12D7-7CC2-47E0-8E1C-A5BA52C4C091Q48373422-31A64C9A-F03C-411C-93BC-2C0298D0A418Q50069820-E2AC56F8-3365-4994-8744-08AAC70A4017Q50603459-12165572-78CD-44D1-B528-513CE11AB3D3Q50770864-51E39D81-9A74-49E6-A60F-8E9EA7679BB0Q51010848-3C604444-43AB-4DED-B2DA-1B60D4DDD58CQ51833653-4969B528-E1DE-43B6-9173-9151F9F6E5BBQ53008520-BFBA0D98-E03E-4325-84D0-01EF331B4FC3Q54774369-21EAF2C4-090B-4422-9590-99DEE4359D9EQ56967485-18EF3B2B-96CC-4B19-BAF4-AEA4F7252CF2Q56971945-ED681856-E0DF-4EF2-9268-DC80531D6955Q56973713-294B59E5-AFF0-4DEE-8E79-D3C2A093633BQ57006319-08DCBDE7-FE4A-4BEC-BC54-0D0376475318
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Vittorio Montefusco
@ast
Vittorio Montefusco
@en
Vittorio Montefusco
@es
Vittorio Montefusco
@nl
Vittorio Montefusco
@sl
type
label
Vittorio Montefusco
@ast
Vittorio Montefusco
@en
Vittorio Montefusco
@es
Vittorio Montefusco
@nl
Vittorio Montefusco
@sl
prefLabel
Vittorio Montefusco
@ast
Vittorio Montefusco
@en
Vittorio Montefusco
@es
Vittorio Montefusco
@nl
Vittorio Montefusco
@sl
P1053
D-1133-2017
P106
P1153
6602821190
P21
P31
P3829
P496
0000-0001-7842-3386